Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice

Area of Science:

• Microbiology
• Infectious Diseases
• Bacteriophage Therapy

Background:

• Nosocomial respiratory infections caused by methicillin-resistant Staphylococcus aureus (MRSA) pose a significant threat, potentially leading to fatal systemic infections.
• Bacteriophage therapy presents a promising alternative for combating critical infections, particularly those caused by antibiotic-resistant bacteria.
• Phage S13' has been previously identified as a potential candidate for therapeutic applications against MRSA.

Purpose of the Study:

• To evaluate the efficacy of phage S13' in a mouse model of lung-derived septicemia caused by MRSA.
• To assess the in vitro lytic activity of phage S13' against hospital-acquired MRSA strains.

Main Methods:

• A mouse model of MRSA-induced lung-derived septicemia was established.
• Intraperitoneal administration of phage S13' was performed at 6 hours post-infection.
• In vitro experiments were conducted to determine the lytic activity of phage S13' against clinical MRSA isolates.

Main Results:

• Intraperitoneal administration of phage S13' significantly reduced infection severity in the mouse model.
• Phage S13' treatment led to the rescue of infected mice, improving survival rates.
• In vitro assays demonstrated that phage S13' efficiently lyses hospital-acquired MRSA strains responsible for pneumonia-associated bacteremia.

Conclusions:

• Phage S13' therapy shows potential as a viable treatment option for staphylococcal lung-derived septicemia.
• Bacteriophage therapy offers a promising strategy to combat MRSA infections, especially in the context of rising antibiotic resistance.
• Further research into phage S13' could pave the way for novel therapeutic interventions against severe bacterial infections.